Administration of methylprednisolone to prevent severe ovarian hyperstimulation syndrome in patients undergoing in vitro fertilization

Fertility and Sterility

Volumn 78, Issue 3, 2002, Pages 529-533

  Lainas, Trifon ^a   Petsas, Georgios ^a   Stavropoulou, Georgia ^a   Alexopoulou, Efthymia ^b   Iliadis, George ^a   Minaretzis, Dimitrios ^a  

^a IVF Unit   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

In vitro fertilization; Methylprednisolone; Ovarian hyperstimulation syndrome; Prevention

Indexed keywords

BUSERELIN ACETATE; METHYLPREDNISOLONE; RECOMBINANT FOLLITROPIN; TRIPTORELIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; FEMALE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; MAJOR CLINICAL STUDY; OOCYTE; OVARY HYPERSTIMULATION; PRIORITY JOURNAL;

ADULT; FEMALE; FERTILIZATION; FERTILIZATION IN VITRO; GLUCOCORTICOIDS; HUMANS; METHYLPREDNISOLONE; OOCYTES; OVARIAN HYPERSTIMULATION SYNDROME; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 0036733862     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(02)03290-9     Document Type: Article

References (32)

1. The ovarian hyperstimulation syndrome
2. Ovarian hyperstimulation syndrome; a current survey
3. Ovarian hyperstimulation syndrome
4. Thromboembolic phenomena after ovarian stimulation with human menopausal gonadotropins
5. Prevention and treatment of ovarian hyperstimulation syndrome
6. Direct correlation between plasma rennin activity and the severity of ovarian hyperstimulation syndrome
7. Severe ovarian hyperstimulation syndrome. Role of peripheral vasodilation
8. Severe ovarian hyperstimulation syndrome; serum and ascitic fluid concentrations of vascular endothelial growth factor
9. The pathogenesis of ovarian hyperstimulation syndrome; in vivo studies investigating the role of interleukin-1β, interleukin-6, and vascular endothelial growth factor
10. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization
11. Are there predictive criteria of complicated ovarian hyperstimulation syndrome in IVF?
12. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome
13. Severe hyperstimulation syndrome in assisted reproductive technology; definition of high risk groups
14. The prevention of ovarian hyperstimulation syndrome
15. Severe hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization a European series and a proposal for prevention
16. An epidemic of severe OHSS; a price we have to pay?
17. Decreasing the risk of ovarian hyperstimulation syndrome
18. The luteinizing hormone surge-the final stage in ovulation induction; modern aspects of ovulation triggering
19. Prevention of ovarian hyperstimulation syndrome; novel strategies
20. Does withholding gonadotropin administration prevent severe ovarian hyperstimulation syndrome?
21. Severe ovarian hyperstimulation syndrome; is it really preventable by prophylactic intravenous albumin?
22. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme; a randomized placebo-controlled trial
23. The immunotherapy during in vitro fertilization and embryo transfer cycles in infertile patients with endometriosis
24. The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization; a prospective randomized study
25. Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer; a modified 'coasting' strategy based on ultrasound for identification of high-risk patients
26. Human menopausal gonadotropins for anovulation and sterility
27. Ovarian hyperstimulation following ovulation induction with human menopausal gonadotropin
28. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome
29. Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration
30. Poor responder-high responder; the importance of soluble vascular endothelial growth factor receptor 1 in ovarian stimulation protocols
31. Corticosteroids inhibit the expression of vascular endothelial growth factor gene in human vascular smooth muscle cells
32. The microcirculation and inflammation; site of action of glucocorticoids